Your browser doesn't support javascript.
loading
Economic evaluation of highly purified human menotropin or recombinant follicle-stimulating hormone for controlled ovarian stimulation in high-responder patients: analysis of the Menopur in Gonadotropin-releasing Hormone Antagonist Single Embryo Transfer-High Responder (MEGASET-HR) trial.
Robins, Jared C; Khair, Andrew F; Widra, Eric A; Alper, Michael M; Nelson, Winnie W; Foster, Eric D; Sinha, Anshul; Ando, Masakazu; Heiser, Patrick W; Daftary, Gaurang S.
Affiliation
  • Robins JC; Northwestern University, Chicago, Illinois.
  • Khair AF; Ferring Pharmaceuticals, Inc., Parsippany, New Jersey.
  • Widra EA; Shady Grove Fertility, Rockville, Maryland.
  • Alper MM; Boston IVF, Waltham, Massachusetts.
  • Nelson WW; Ferring Pharmaceuticals, Inc., Parsippany, New Jersey.
  • Foster ED; Ferring Pharmaceuticals, Inc., Parsippany, New Jersey.
  • Sinha A; Ferring Pharmaceuticals, Inc., Parsippany, New Jersey.
  • Ando M; Ferring Pharmaceuticals, Inc., Parsippany, New Jersey.
  • Heiser PW; Ferring Pharmaceuticals, Inc., Parsippany, New Jersey.
  • Daftary GS; Ferring Pharmaceuticals, Inc., Parsippany, New Jersey.
F S Rep ; 1(3): 257-263, 2020 Dec.
Article in En | MEDLINE | ID: mdl-34223253
ABSTRACT

OBJECTIVE:

To determine the cost of achieving a live birth after first transfer using highly purified human menotropin (HP-hMG) or recombinant follicle-stimulating hormone (FSH) for controlled ovarian stimulation in predicted high-responder patients in the Menopur in Gonadotropin-releasing hormone Antagonist Single Embryo Transfer-High Responder (MEGASET-HR) trial.

DESIGN:

Cost minimization analysis of trial results.

SETTING:

Thirty-one fertility centers. PATIENTS Six hundred and nineteen women with serum antimüllerian hormone ≥5 ng/mL.

INTERVENTIONS:

Controlled ovarian stimulation with HP-hMG or recombinant FSH in a gonadotropin-releasing hormone (GnRH) antagonist assisted reproduction cycle where fresh transfer of a single blastocyst was performed unless ovarian response was excessive whereupon all embryos were cryopreserved and patients could undergo subsequent frozen blastocyst transfer within 6 months of randomization. MAIN OUTCOME

MEASURES:

Mean cost of achieving live birth after first transfer (fresh or frozen).

RESULTS:

First-transfer efficacy, defined as live birth after first fresh or frozen transfer, was 54.5% for HP-hMG and 48.0% for recombinant FSH (difference 6.5%). Average cost to achieve a live birth after first transfer (fresh or frozen) was lower with HP-hMG compared with recombinant FSH. For fresh transfers, the cost was lower with HP-hMG compared with recombinant FSH. The average cost to achieve a live birth after first frozen transfer was also lower in patients treated with HP-hMG compared with recombinant FSH.

CONCLUSIONS:

Treatment of predicted high-responders with HP-hMG was associated with lower cost to achieve a live birth after first transfer compared with recombinant FSH. CLINICAL TRIAL REGISTRATION NUMBER NCT02554279.
Key words

Full text: 1 Database: MEDLINE Type of study: Clinical_trials / Health_economic_evaluation / Prognostic_studies Language: En Year: 2020 Type: Article

Full text: 1 Database: MEDLINE Type of study: Clinical_trials / Health_economic_evaluation / Prognostic_studies Language: En Year: 2020 Type: Article